Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn’s Disease Response to Infliximab, as Assessed by Calprotectin Log Drop

Abstract

Background: Cytokines emerge as possible biomarkers of response in Crohn’s disease (CD). We aimed to determine the plasmatic cytokine profiles of active CD patients who started infliximab (IFX) treatment and their capacity to predict the response to IFX. Methods: A total of 30 active CD patients receiving an induction therapy of IFX were enrolled in the study. Peripheral blood samples pretreatment were collected. Concentrations of 15 cytokines were measured by Luminex technology. Responses to IFX were evaluated by the drop in fecal calprotectin based on its logarithm-transformed values. A random forest (RF) predictive model was used for data analyses. Results: Samples of 22 patients were analyzed. The RF model ranked the following cytokines as the top predictors of the response: tumor necrosis factor alpha (TNFα), interleukin (IL)-13, oncostatin M (OSM), and IL-7 (p < 0.005). Partial dependency plots showed that high levels of IL-13 pretreatment, low TNFα levels, and low IL-7 levels were associated with a favorable IFX response. Increased levels of OSM and TNFα predicted unfavorable responses to IFX. Conclusions: We here show that a log drop in calprotectin strongly correlates with clinical parameters and it can be proposed as a useful objective clinical response predictor. Plasma TNFα, IL-13, Il-7, and OSM network could predict CD response to IFX before induction therapy, as assessed by calprotectin log drop.

Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation

“…In the largest pediatric prospective inception cohort study (RISK study) in 913 CD patients, several risk factors of B2 and B3 disease behavior were identified but with no specific conclusions regarding the prediction of anti-TNF efficacy (48). Recent studies identified various serological or genetic predictors of anti-TNF response (49–54); however, these factors were not measured in our patients and thus cannot be discussed. We identified a combination of ASCA negativity and pANCA positivity as the strongest independent predictors of treatment escalation in the multivariate model.…”

Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis

“…In this study, macrophagic OSM expression had a strong correlation with mucosal OSM. OSM expression is found consistently higher in inflamed parts of intestine where it promotes inflammation in gut stromal cells in response to microbial challenges[ 22 ]. O'Connell et al [ 26 ] who studied 21 acute severe ulcerative colitis patients observed a greater degree of immunostaining in the mucosal epithelial cells rather than stromal cells which provides impetus for studying OSM immunostaining in different IBD phenotypes.…”

Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?

“…However, Mateos et al. ( 53 ) recently measured the plasma concentration of TNF pretreatment in 30 active CD patients with infliximab (IFX) induction therapy and reported that increased TNFα levels were associated with an unfavorable response to IFX ( 53 ). Therefore, the reliability of a serological TNF level as a biomarker in predicting the anti-TNF response in patients with IBD is still unclear.…”